A national battle over drug prices hit a snag this week when federal lawmakers delayed a vote on a bipartisan bill that seeks to expand transparency of the multi-billion-dollar health care industry. But the impasse over the Lower Costs, More Transparency Act in Congress is hardly a death knell for its provisions aimed at pharmacy benefit managers.
The previously obscure PBMs — companies that contract with health plans to administer prescription drug benefits — have been the subject of a flurry of state regulations in recent years as policy makers, frustrated with federal inaction, have taken their own steps to bring drug prices under control.
Already a subscriber? Sign in